Who are Plasbumin®-20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GoodSense Eye Drops Advanced Relief Moisturizer, Humanalbumin 5%, HES 130/04, tetrastarch (Voluven), HES 130/0.42 + electrolyte solution, succinylated gelatin injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/plasbumin-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Plasbumin®-20 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasbumin®-20 (Plasbumin®-20) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plasma volume expander; Colloid solution. Area: Critical Care; Hematology.

phase 3 Plasma volume expander; Colloid solution Plasma oncotic pressure regulation Critical Care; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Plasbumin®-20 (Plasbumin®-20) — Healthgen Biotechnology Corp.. Plasbumin-20 is a human serum albumin solution that acts as a plasma volume expander and colloid to restore intravascular oncotic pressure and improve tissue perfusion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Plasbumin®-20 TARGET	Plasbumin®-20	Healthgen Biotechnology Corp.	phase 3	Plasma volume expander; Colloid solution	Plasma oncotic pressure regulation
GoodSense Eye Drops Advanced Relief Moisturizer	DEXTRAN	Allergan	marketed	Plasma Volume Expander [EPC]		1978-01-01
Humanalbumin 5%	Humanalbumin 5%	Medical University of Vienna	marketed	Plasma volume expander; blood product derivative
HES 130/04	HES 130/04	K. C. Rasmussen	marketed	Synthetic colloid / Plasma volume expander
tetrastarch (Voluven)	tetrastarch (Voluven)	University of the Philippines	marketed	Synthetic colloid / Plasma volume expander
HES 130/0.42 + electrolyte solution	HES 130/0.42 + electrolyte solution	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
succinylated gelatin injection	succinylated gelatin injection	Nanjing Chia-tai Tianqing Pharmaceutical	marketed	Colloid plasma volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plasma volume expander; Colloid solution class)

Healthgen Biotechnology Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Plasbumin®-20 — Competitive Intelligence Brief. https://druglandscape.com/ci/plasbumin-20. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing